Cohance Lifesciences Ltd. Financials: Quarterly Results
Revenue
571.17
Cr.
PAT
66.39
Cr.
EBITDA
92.53
Cr.
Cohance Lifesciences Ltd. Q1FY26 Financial Metrics
| Indicator | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 555.57 | 549.31 | 402.02 | 307.15 | 257.72 |
| Total Income From Operations (Cr.) | 555.57 | 549.31 | 402.02 | 307.15 | 257.72 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 92.53 | 81.04 | 57.35 | 113.06 | 101.17 |
| P/L Before Exceptional Items & Tax (Cr.) | 83.77 | 70.86 | 51.60 | 109.73 | 99.50 |
| P/L After Tax from Ordinary Activities (Cr.) | 66.39 | 46.40 | 38.73 | 83.29 | 81.98 |
| Net Profit/Loss For the Period (Cr.) | 66.39 | 46.40 | 38.73 | 83.29 | 81.98 |
| Basic EPS | 1.94 | 1.28 | 1.65 | 3.26 | 3.23 |
FAQs
Cohance Lifesciences Ltd. announced its quarterly results for Q1 FY2026 on August 13, 2025.
In Q1 FY2026, Cohance Lifesciences Ltd. are as follows:
Revenue: ₹571.17 crore
Net Profit: ₹66.39 crore.
For Q1 FY2026, Cohance Lifesciences Ltd. posted ₹571.17 crore in revenue and ₹66.39 crore in net profit.
Past quarterly results for Cohance Lifesciences Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.